GT
GSK icon

Greenleaf Trust’s GSK GSK Stock Holding History

Greenleaf Trust’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
8,024
+339
+4% +$17.9K ﹤0.01% 566
2026
Q1 		$424K Buy
7,685
+83
+1% +$4.5K ﹤0.01% 534
2025
Q4 		$373K Buy
7,602
+109
+1% +$5.08K ﹤0.01% 569
2025
Q3 		$323K Sell
7,493
-201
-3% -$7.85K ﹤0.01% 616
2025
Q2 		$295K Buy
7,694
+224
+3% +$8.56K ﹤0.01% 634
2025
Q1 		$289K Buy
7,470
+60
+0.8% +$2.2K ﹤0.01% 658
2024
Q4 		$251K Sell
7,410
-859
-10% -$30.9K ﹤0.01% 717
2024
Q3 		$338K Sell
8,269
-2,020
-20% -$82.6K ﹤0.01% 626
2024
Q2 		$396K Buy
10,289
+2,048
+25% +$86.1K ﹤0.01% 534
2024
Q1 		$353K Sell
8,241
-2,115
-20% -$87.2K ﹤0.01% 559
2023
Q4 		$384K Sell
10,356
-4,808
-32% -$173K ﹤0.01% 537
2023
Q3 		$550K Buy
15,164
+2,231
+17% +$79.2K 0.01% 412
2023
Q2 		$461K Buy
12,933
+1,154
+10% +$41.4K ﹤0.01% 471
2023
Q1 		$419K Buy
11,779
+655
+6% +$22.9K ﹤0.01% 499
2022
Q4 		$391K Buy
11,124
+1,682
+18% +$56K 0.01% 508
2022
Q3 		$278K Buy
9,442
+4,040
+75% +$153K ﹤0.01% 566
2022
Q2 		$294K Sell
5,402
-1,016
-16% -$56.1K ﹤0.01% 559
2022
Q1 		$349K Sell
6,418
-1,199
-16% -$65.1K ﹤0.01% 539
2021
Q4 		$420K Buy
7,617
+2,311
+44% +$120K ﹤0.01% 481
2021
Q3 		$253K Sell
5,306
-1,662
-24% -$83.5K ﹤0.01% 630
2021
Q2 		$347K Buy
6,968
+1,026
+17% +$49.3K ﹤0.01% 516
2021
Q1 		$265K Sell
5,942
-975
-14% -$44.3K ﹤0.01% 593
2020
Q4 		$318K Sell
6,917
-2,577
-27% -$118K ﹤0.01% 440
2020
Q3 		$447K Sell
9,494
-1,269
-12% -$63.6K 0.01% 309
2020
Q2 		$549K Sell
10,763
-2,135
-17% -$110K 0.01% 252
2020
Q1 		$611K Buy
12,898
+184
+1% +$9.81K 0.01% 196
2019
Q4 		$747K Buy
12,714
+258
+2% +$14.4K 0.01% 206
2019
Q3 		$665K Buy
12,456
+916
+8% +$47.1K 0.01% 227
2019
Q2 		$577K Sell
11,540
-935
-7% -$46.9K 0.01% 249
2019
Q1 		$652K Sell
12,475
-691
-5% -$34.5K 0.01% 213
2018
Q4 		$629K Sell
13,166
-2,143
-14% -$106K 0.01% 219
2018
Q3 		$769K Sell
15,309
-43
-0.3% -$2.19K 0.01% 207
2018
Q2 		$774K Buy
15,352
+4,847
+46% +$244K 0.01% 195
2018
Q1 		$513K Buy
10,505
+1,630
+18% +$75.9K 0.01% 236
2017
Q4 		$394K Buy
8,875
+7,725
+672% +$357K 0.01% 284
2017
Q3 		$58K Sell
1,150
-7,836
-87% -$398K ﹤0.01% 429
2017
Q2 		$484K Buy
8,986
+136
+2% +$7.25K 0.01% 205
2017
Q1 		$466K Buy
+8,850
New +$449K 0.01% 165
2015
Q2 		– Sell
-20,539
Closed -$1.19M – 164
2015
Q1 		$1.19M Buy
20,539
+2,195
+12% +$126K 0.04% 72
2014
Q4 		$980K Buy
18,344
+3,164
+21% +$177K 0.03% 78
2014
Q3 		$872K Buy
15,180
+3,582
+31% +$220K 0.03% 84
2014
Q2 		$775K Buy
11,598
+872
+8% +$59K 0.02% 92
2014
Q1 		$716K Sell
10,726
-1,044
-9% -$70.6K 0.02% 94
2013
Q4 		$785K Sell
11,770
-160
-1% -$10.4K 0.03% 90
2013
Q3 		$748K Sell
11,930
-988
-8% -$63.6K 0.03% 90
2013
Q2 		$807K Buy
+12,918
New +$820K 0.03% 83

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return

Greenleaf Trust's GSK Position: Q2 2026 in Review

Greenleaf Trust increased its GSK (GSK) stake by 4.4% in Q2 2026, buying an estimated $17.9K and bringing the position to 8,024 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #566.

Greenleaf Trust first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.19M in Q1 2015. 214 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Greenleaf Trust held 8,024 shares of GSK worth $421K as of Q2 2026.
  • Greenleaf Trust bought 339 GSK shares in Q2 2026, an estimated $17.9K.
  • GSK made up ﹤0.01% of Greenleaf Trust's portfolio in Q2 2026, its #566 holding.
  • Greenleaf Trust first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
  • Greenleaf Trust's GSK position peaked at $1.19M in Q1 2015.
  • 214 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.